Search Results
Mar 17, 2026, 07:35 ET Knight Therapeutics Anuncia Aprovação de Indicação Adicional para MINJUVI® (tafasitamabe) no Brasil
eventos futuros, exceto conforme exigido por lei.Referências:MINJUVI (tafasitamab) Powder for solution for infusion 200 mg ANVISA; precribing information January, 2026. Accessed February 19th 2026.
More news about: Knight Therapeutics Inc.
Mar 17, 2026, 07:35 ET Knight Therapeutics anuncia la aprobación de una indicación adicional para MINJUVI® (tafasitamab) en Brasil
futuros, excepto según lo requiera la ley.Referencias:MINJUVI (tafasitamab) polvo para solución para infusión 200 mg – ANVISA; información para prescribir, enero de 2026. Consultado el 19 de febrero de 2026.Kanters S, Ball G, Kahl B, et al. Clinical outcomes
More news about: Knight Therapeutics Inc.
Mar 17, 2026, 06:00 ET 口服小分子胰澱素受體激動劑ASC39在臨床前模型中顯示出類似eloralintide的胰澱素選擇性與療效
pM。這些數據表明，相較於hCTR，ASC39對hAMY1R具有高度選擇性，且ASC39對hAMY1R的選擇性與eloralintide相當。ASC39與eloralintide對hAMY1R的選擇性比對hCTR的分別高40倍和64倍。在一項頭對頭飲食誘導肥胖（DIO）大鼠研究中，與接受安慰劑給藥的肥胖大鼠相比，ASC39每日口服給藥顯示出具有統計學顯著性的體重下降，與eloralintide相當（見表1）。每日一次口服給藥5 mg/kg的ASC39，連續給藥6天，產生了顯著的經安慰劑校正後的體重下降6.6%。每三天一次皮下注射3 nmol/kg的eloralintide，連續6天，產生了顯著的經安慰劑校正後的體重下降5.6%，與文獻數據一致[1]。表1. ASC39每日一次口服給藥連續6天產生了具有統計學顯著性的體重下降，其療效與eloralintide的相當。
More news about: 歌禮製藥有限公司
Mar 17, 2026, 06:00 ET Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models
administration of ASC39 resulted in statistically significant weight loss which was comparable to eloralintide (Table 1). Once-daily oral administration of 5 mg/kg ASC39 for 6 consecutive days produced significant placebo adjusted weight loss of 6.6%. Once-every-three-day subcutaneous (SQ) administration of 3
More news about: Ascletis Pharma Inc.
Mar 16, 2026, 15:47 ET SmartyPants Vitamins Launches New OB-GYN Co-Developed Prenatal Capsule Designed To Support Baby's Brain and Development*
Plus Multivitamin Capsules include:480 mg choline to support fetal brain and spinal cord development*667mcg folate as methylfolate to support fetal nervous system development*50mg of DHA included as part of a thoughtfully balanced formulaIodine
More news about: SmartyPants Vitamins
Mar 16, 2026, 09:06 ET LEGACY CANNABIS BRAND ANNOUNCES NATIONWIDE PRODUCT EXPANSION
Dreamy Blueberry - 1:1:1, 100mg THC, 100mg CBG, 100mg CBN (Sleep Recover)Sleepy Watermelon - 1:2:2, 50mg THC, 100mg CBN, 100mg CBD (Blissful Sleep)Midnight Prickly Pear - 1:1:1, 100mg THC, 100mg CBN, 100mg CBD (Deep Sleep)Jamberry - 1:1, 100mg THC, 100mg CBN (Classic)The
More news about: Smokiez Edibles
Mar 16, 2026, 08:00 ET Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
toxicity.The MTD as assessed by an independent safety review committee, provided AL001's lithium at a lithium carbonate equivalent dose of 240 mg TID. This dose was selected to maintain plasma lithium concentrations below levels commonly associated with toxicity and is designed to be unlikely to
More news about: Alzamend Neuro, Inc.
Mar 16, 2026, 08:00 ET Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation
arteritis (GCA), polyarticular juvenile idiopathic arthritis (PJIA) and systemic juvenile idiopathic arthritis (SJIA). AVTOZMA SC is available in a 162 mg/0.9 mL solution for injection in a single-dose prefilled syringe or a single-dose prefilled autoinjector, allowing patients the flexibility and convenience
More news about: Celltrion
Mar 16, 2026, 07:00 ET Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis
52-week global, multicenter, randomized, double-blind, placebo-controlled Phase 3 studies aimed at assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA®) in adult patients with active psoriatic arthritis.Learn more about the studies at clinicaltrials.gov (INSPIRE-1 NCT04314544
More news about: Sun Pharmaceutical Industries Inc., USA (Sun Pharma)
Mar 16, 2026, 06:45 ET Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
therapies.7 EBGLYSS 250 mg/2 mL injection is dosed as a single monthly maintenance injection following the initial phase of treatment. The recommended initial starting dose of EBGLYSS is 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16 or
More news about: Eli Lilly and Company
Mar 14, 2026, 12:39 ET ¿La revolución limpia del café? Venturi Bold Brew desafía a las bebidas de café cargadas de azúcar con una infusión fría de nitro más limpia
Stout Truffle, una rica experiencia de café estilo postre. Cada lata está formulada para ofrecer un potente aumento de aproximadamente 276 mg de cafeína de origen natural, lo que brinda a los consumidores un impulso sostenido comparable a casi dos tazas de café, sin depender de aditivos
More news about: Venturi Bold Brew
Mar 13, 2026, 20:29 ET Coffee's Clean Revolution? Venturi Bold Brew Challenges Sugar-Loaded Café Drinks With a Cleaner Nitro Cold Brew
and Stout Truffle, a rich, dessert-style coffee experience. Each can is formulated to deliver a powerful lift of roughly up to 276 mg of naturally sourced caffeine, giving consumers a sustained boost comparable to nearly two cups of coffee, without relying on artificial energy additives.The
More news about: Venturi Bold Brew
Mar 13, 2026, 15:03 ET ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol
stroke, the LDL-C goal should be less than 100 mg/dL for those at borderline or intermediate risk and less than 70 mg/dL in those at high risk. For individuals with ASCVD who are at very high risk of ASCVD events, the LDL-C goal should be less than 55 mg/dL for secondary prevention of cardiac events."In
More news about: American College of Cardiology
Mar 13, 2026, 13:21 ET Restore. Refuel. Refresh: Javvy Coffee Debuts a New Category With Clear Protein Refreshers
hitting Target stores soon.Protein Refresher Highlights:10g of Clear Protein per scoop3g of Fiber45mg of Caffeine0g of SugarNo Artificial Sweeteners, Flavors, or ColorsPrebioticsCollagenElectrolytesEasy
More news about: Javvy Coffee
Mar 13, 2026, 07:39 ET Motocicleta impulsiona geração de renda em Minas Gerais
De acordo com a Hanbai Motos (Concessionária Honda de Belo Horizonte/MG), parte significativa das vendas recentes está associada ao uso profissional, sobretudo por trabalhadores autônomos e pequenos empreendedores. Em
More news about: Hanbai Motos
Mar 13, 2026, 06:06 ET 雲頂新耀合作夥伴新橋生物與Visara宣佈VIS-101 IIa期臨床在濕性AMD取得積極頂線數據
6mg（25例）3mg（13例）
More news about: 雲頂新耀
Mar 12, 2026, 23:09 ET WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation
clinical and commercial use, including its high-throughput formulation development platform WuXiHigh™, which enables protein concentrations of up to 230mg/mL and achieves viscosity reduction by up to 90%.Building on its innovative technology platforms, WuXi Biologics consistently leads the industry
More news about: WuXi Biologics
Mar 12, 2026, 08:00 ET Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management
group using traditional finger sticks. They also spent about 2.5 more hours a day (10.4% increase)2 in a healthy glucose range (70–180 mg/dL). Participants were on basal insulin with either an SGLT2 inhibitor or a GLP‑1 receptor agonist, indicating meaningful benefit even among people already
More news about: Abbott
Mar 12, 2026, 04:54 ET Studie zeigt: FreeStyle Libre Technologie verhilft Menschen mit Typ-2-Diabetes und Basalinsulin zu einem besseren Glukosemanagement
Blutzuckermessung. Darüber hinaus verbrachten sie durchschnittlich rund 2,5 Stunden pro Tag (10,4 % Zunahme)2 mehr Zeit im Zielbereich (70 bis 180 mg/dl). Die Studienteilnehmenden erhielten einmal täglich Basalinsulin sowie zusätzlich entweder einen SGLT2-Inhibitor oder einen GLP-1-Rezeptoragonisten,
More news about: Abbott
Mar 12, 2026, 03:00 ET Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management
group using traditional finger sticks. They also spent about 2.5 more hours a day (10.4% increase)2 in a healthy glucose range (70–180 mg/dL). Participants were on basal insulin with either an SGLT2 inhibitor or a GLP‑1 receptor agonist, indicating meaningful benefit even among people already
More news about: Abbott
Mar 11, 2026, 08:49 ET DifGen Pharmaceuticals Receives FDA Approval for Generic Mesalamine Extended-Release Capsules USP, 250mg and 500mg
has approved its Abbreviated New Drug Application (ANDA) for Mesalamine Extended-Release Capsules USP, 250 mg and 500 mg with a Competitive Generic Therapy (CGT) designation granted for the 250mg strength. The approved product is therapeutically equivalent (AB-rated) to the reference listed drug, PENTASA®
More news about: DifGen Pharmaceuticals LLC
Mar 11, 2026, 07:00 ET THE PERFECT SIP FOR ANY MOMENT: PANERA BREAD LAUNCHES NEW ENERGY REFRESHERS AND FRESCAS
approximately 28 mg caffeine in a 20 fl. oz. cup, with ice and 42 mg caffeine in 30 fl. oz. cup, with ice.Passionfruit Paradise Energy Refresher – A caffeinated blend of passionfruit, guava and orange flavors, infused with fresh pineapple. These offer approximately 28 mg caffeine in
More news about: Panera
Mar 10, 2026, 10:43 ET La percée de 0,05 UE/mg : Comment Sino Biological ProPure™ redéfinit les normes d'endotoxines ultra-faibles
protéines sans endotoxines ProPure™ avec des niveaux inférieurs à la limite de quantification (BQL) (< 0,05 UI/mg), ce qui est supérieur à la norme industrielle (0,5 UI/mg selon l'USP). Le choix des protéines ProPure™ favorise des résultats expérimentaux précis, renforce la fiabilité des données
More news about: Sino Biological, Inc.
Mar 10, 2026, 10:42 ET Der 0,05 EU/mg-Durchbruch: Wie Sino Biological ProPure™ den Standard für extrem niedrige Endotoxinwerte neu definiert
Texas produziert ProPure™ Endotoxin-freie Proteine mit Werten unterhalb der Quantifizierungsgrenze (BQL) (< 0,05 EU/mg), die den heutigen Industriestandard (0,5 EU/mg gemäß USP <85>) deutlich übertreffen. Die Wahl von ProPure™-Proteinen unterstützt genaue Versuchsergebnisse, erhöht die
More news about: Sino Biological, Inc.
Mar 10, 2026, 10:16 ET El avance de 0,05 EU/mg:cómo Sino Biological ProPure™ está redefiniendo el estándar de endotoxinas ultrabajas
produce proteínas ProPure™ libres de endotoxinas con niveles inferiores al límite de cuantificación (LCC) (< 0,05 UE/mg), que superan el estándar de la industria (0,5 UE/mg según USP <85>). La elección de las proteínas ProPure™ garantiza resultados experimentales precisos, mejora la fiabilidad
More news about: Sino Biological, Inc.